Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a Buy rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) and raises the price target from $22 to $32.
July 26, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Kiniksa Pharmaceuticals and raises the price target from $22 to $32.
The raised price target by Goldman Sachs indicates a positive outlook for Kiniksa Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100